Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 27 citing articles:

Frailty and Cancer: Current Perspectives on Assessment and Monitoring
Valentin Goede
Clinical Interventions in Aging (2023) Vol. Volume 18, pp. 505-521
Open Access | Times Cited: 76
TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation
Shabbir M.H. Alibhai, Martine Puts, Rana Jin, et al.
Journal of Geriatric Oncology (2024) Vol. 15, Iss. 6, pp. 101750-101750
Open Access | Times Cited: 5
Geriatric assessment for the practicing clinician: The why, what, and how
Allison Magnuson, Kah Poh Loh, Fiona Stauffer, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 6, pp. 496-518
Open Access | Times Cited: 4
Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer
Charles Gaber, Ebere Okpara, Abdullah I. Abdelaziz, et al.
Journal of Geriatric Oncology (2025) Vol. 16, Iss. 2, pp. 102148-102148
Open Access
The Evolution of Geriatric Oncology and Geriatric Assessment over the Past Decade
Darryl Outlaw, Maya Abdallah, Luiz A. Gil-Jr, et al.
Seminars in Radiation Oncology (2022) Vol. 32, Iss. 2, pp. 98-108
Open Access | Times Cited: 18
Prospective comparison of the value of CARG, G8, and VES-13 toxicity tools in predicting chemotherapy-related toxicity in older Turkish patients with cancer
Eyyüp Çavdar, Yakup İriağaç, Kubilay Karaboyun, et al.
Journal of Geriatric Oncology (2022) Vol. 13, Iss. 6, pp. 821-827
Closed Access | Times Cited: 17
The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer
Valerie S. Kim, Helen Yang, Narhari Timilshina, et al.
Journal of Geriatric Oncology (2023) Vol. 14, Iss. 2, pp. 101417-101417
Closed Access | Times Cited: 10
Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review
Nabiel Mir, Olivia Burke, Samuel J. Yates, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 10
Geriatric assessment in the older adult with genitourinary cancer: A narrative review
Surbhi Singhal, Julianna G. Marwell, Ali Raza Khaki
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer
Efthymios Papadopoulos, Andy Kin On Wong, Sharon Hiu Ching Law, et al.
PLoS ONE (2023) Vol. 18, Iss. 6, pp. e0286381-e0286381
Open Access | Times Cited: 7
Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
Shruti Parshad, Amanjot K. Sidhu, Nabeeha Khan, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2783-2783
Open Access | Times Cited: 8
Symptom experiences of older adults during treatment for metastatic prostate cancer: A qualitative investigation
Milothy Parthipan, Gregory Feng, Nelly Toledano, et al.
Journal of Geriatric Oncology (2022) Vol. 14, Iss. 1, pp. 101397-101397
Closed Access | Times Cited: 8
Outcomes in studies regarding older patients with prostate cancer: A systematic review
Kim F.T. Jochems, Dominik Menges, Dafne N. Sanchez, et al.
Journal of Geriatric Oncology (2024) Vol. 15, Iss. 5, pp. 101763-101763
Open Access | Times Cited: 1
Assessing the ability of the Cancer and Aging Research Group tool to predict chemotherapy toxicity in older Japanese patients: A prospective observational study
Masanobu Uchiyama, Motoyasu Miyazaki, Toshinobu Hayashi, et al.
Journal of Geriatric Oncology (2024) Vol. 15, Iss. 6, pp. 101814-101814
Open Access | Times Cited: 1
Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer
Efthymios Papadopoulos, Andy Kin On Wong, Sharon Hiu Ching Law, et al.
Canadian Urological Association Journal (2024) Vol. 18, Iss. 12
Open Access | Times Cited: 1
The applicability of the Cancer and Aging Research Group (CARG) chemotherapy toxicity prediction tool
Neha Pathak, Tomohiro F. Nishijima, Eyyüp Çavdar
Journal of Geriatric Oncology (2024), pp. 102070-102070
Closed Access | Times Cited: 1
Frailty in Older Adults with Prostate Cancer
Neha Pathak, Efthymios Papadopoulos, Vikaash Kumar, et al.
European Urology Oncology (2024)
Open Access | Times Cited: 1
Management of prostate cancer in older patients
Shintaro Narita, Shingo Hatakeyama, Shinichi Sakamoto, et al.
Japanese Journal of Clinical Oncology (2022) Vol. 52, Iss. 6, pp. 513-525
Open Access | Times Cited: 7
Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapy
Giulio Francolini, Giulio Frosini, Vanessa Di Cataldo, et al.
Journal of Geriatric Oncology (2022) Vol. 14, Iss. 1, pp. 101411-101411
Closed Access | Times Cited: 6
An overview of chemotherapy toxicity prediction tools in older adults with cancer: A young international society of geriatric oncology and nursing and allied health initiative
Nicolò Matteo Luca Battisti, Sukeshi Patel Arora
Journal of Geriatric Oncology (2021) Vol. 13, Iss. 4, pp. 521-525
Open Access | Times Cited: 7
Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers
Tomohiro F. Nishijima, Allison M. Deal, Grant R. Williams, et al.
Cancer (2022) Vol. 128, Iss. 10, pp. 1929-1936
Open Access | Times Cited: 5
Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer
Helen Yang, Valerie S. Kim, Narhari Timilshina, et al.
Journal of Geriatric Oncology (2022) Vol. 14, Iss. 1, pp. 101395-101395
Closed Access | Times Cited: 4
Docetaxel vs androgen-receptor signaling inhibitors (ARSI) as second-line therapy after failure of first-line alternative ARSI for the elderly ≥75 years old with metastatic castration-resistant prostate cancer (mCRPC): a SPARTACUSS – Meet-URO 26 real-world study.
Anna Patrikidou, Calogero Saieva, Richard M. Lee‐Ying, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 6, pp. 102230-102230
Closed Access
The Role of Frailty and Myosteatosis in Predicting All-Cause Mortality in Older Adults with Cancer
Efthymios Papadopoulos, Andy Kin On Wong, Sharon Hiu Ching Law, et al.
Current Oncology (2024) Vol. 31, Iss. 12, pp. 7852-7862
Open Access
Geriatric assessment-informed treatment decision making and downstream outcomes: what are the research priorities?
Tina Hsu, Bonnie Leung, Caroline Mariano
Current Opinion in Supportive and Palliative Care (2021) Vol. 16, Iss. 1, pp. 25-32
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top